Celltrion, which acquired the Asia-Pacific distribution rights for Takeda Pharmaceutical products, used them to create an improved new drug. One of the acquired products, Nesina Met SR, a type 2 diabetes treatment, received approval from the Ministry of Food and Drug Safety.

The Ministry of Food and Drug Safety announced on the 14th that it had approved Celltrion's type 2 diabetes treatment Alogliptin Met SR. This is the first time that Celltrion has received domestic approval for a chronic disease treatment. Alogliptin Met SR appears similar to Nesina Met, which Celltrion acquired from Takeda in 2020 and has domestic licensing rights but is a domestically developed product with a different formulation